Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.
Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults.
"The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events."
Novo Nordisk said it expects to implement the label update within a month.
The company's CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential."
Persons:
Wegovy, —, Martin Holst Lange, Roche, Thomas Schinecker
Organizations:
Novo Nordisk, Novo, European Medical Agency, U.S . Food, Drug Administration
Locations:
Danish, U.S, Swiss